ENTREMED, INC. (NASDAQ:ENMD)

CAPS Rating: 1 out of 5

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.

Featured Broker Partners


Advertisement